Recently, the clinical trials of a high-profile drug called Sotatercept targeting TGF-β showed promise for treating PAH, matching TGF-β ligands to inhibit vascular remodeling and ameliorate disease progression [82]. This evidence concerns the gene TGFB1 and pulmonary arterial hypertension.